Selected research
Industry Research
Ioversol Injection Industry Research Report 2026
Market perspective
The global Ioversol Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Ioversol Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Ioversol Injection market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Ioversol Injection market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Ioversol Injection include GUERBET, Zhejiang Starry Pharmaceutical, Hengrui Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Neptunus Bio-pharmaceutical, Liebel-Flarsheim Company LLC and Bracco Imaging S.p.A., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Ioversol Injection market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Ioversol Injection.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Ioversol Injection Market by Company
GUERBET
Zhejiang Starry Pharmaceutical
Hengrui Pharmaceuticals
Bayer HealthCare Pharmaceuticals
Neptunus Bio-pharmaceutical
Liebel-Flarsheim Company LLC
Bracco Imaging S.p.A.
Ioversol Injection Segment by Type
50mL
75mL
100mL
125mL
Ioversol Injection Segment by Application
Hospital
Clinic
Others
Ioversol Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ioversol Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ioversol Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ioversol Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Ioversol Injection companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 50mL
- 75mL
- 100mL
- 125mL
Applications
- Hospital
- Clinic
- Others
Companies covered
- GUERBET
- Zhejiang Starry Pharmaceutical
- Hengrui Pharmaceuticals
- Bayer HealthCare Pharmaceuticals
- Neptunus Bio-pharmaceutical
- Liebel-Flarsheim Company LLC
- Bracco Imaging S.p.A.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Ioversol Injection by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 50mL
- 2.2.3 75mL
- 2.2.4 100mL
- 2.2.5 125mL
- 2.3 Ioversol Injection by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Ioversol Injection Breakdown Data by Type
- 3.1 Global Ioversol Injection Historic Market Size by Type (2021-2026)
- 3.2 Global Ioversol Injection Forecasted Market Size by Type (2027-2032)
4 Ioversol Injection Breakdown Data by Application
- 4.1 Global Ioversol Injection Historic Market Size by Application (2021-2026)
- 4.2 Global Ioversol Injection Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Ioversol Injection Market Perspective (2021-2032)
- 5.2 Global Ioversol Injection Growth Trends by Region
- 5.2.1 Global Ioversol Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Ioversol Injection Historic Market Size by Region (2021-2026)
- 5.2.3 Ioversol Injection Forecasted Market Size by Region (2027-2032)
- 5.3 Ioversol Injection Market Dynamics
- 5.3.1 Ioversol Injection Industry Trends
- 5.3.2 Ioversol Injection Market Drivers
- 5.3.3 Ioversol Injection Market Challenges
- 5.3.4 Ioversol Injection Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Ioversol Injection Players by Revenue
- 6.1.1 Global Top Ioversol Injection Players by Revenue (2021-2026)
- 6.1.2 Global Ioversol Injection Revenue Market Share by Players (2021-2026)
- 6.2 Global Ioversol Injection Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Ioversol Injection Head Office and Area Served
- 6.4 Global Ioversol Injection Players, Product Type & Application
- 6.5 Global Ioversol Injection Manufacturers Established Date
- 6.6 Global Ioversol Injection Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Ioversol Injection Market Size (2021-2032)
- 7.2 North America Ioversol Injection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Ioversol Injection Market Size by Country (2021-2026)
- 7.4 North America Ioversol Injection Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Ioversol Injection Market Size (2021-2032)
- 8.2 Europe Ioversol Injection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Ioversol Injection Market Size by Country (2021-2026)
- 8.4 Europe Ioversol Injection Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Ioversol Injection Market Size (2021-2032)
- 9.2 Asia-Pacific Ioversol Injection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Ioversol Injection Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Ioversol Injection Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Ioversol Injection Market Size (2021-2032)
- 10.2 South America Ioversol Injection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Ioversol Injection Market Size by Country (2021-2026)
- 10.4 South America Ioversol Injection Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Ioversol Injection Market Size (2021-2032)
- 11.2 Middle East & Africa Ioversol Injection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Ioversol Injection Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Ioversol Injection Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 GUERBET
- 12.1.1 GUERBET Company Information
- 12.1.2 GUERBET Business Overview
- 12.1.3 GUERBET Revenue in Ioversol Injection Business (2021-2026)
- 12.1.4 GUERBET Ioversol Injection Product Portfolio
- 12.1.5 GUERBET Recent Developments
- 12.2 Zhejiang Starry Pharmaceutical
- 12.2.1 Zhejiang Starry Pharmaceutical Company Information
- 12.2.2 Zhejiang Starry Pharmaceutical Business Overview
- 12.2.3 Zhejiang Starry Pharmaceutical Revenue in Ioversol Injection Business (2021-2026)
- 12.2.4 Zhejiang Starry Pharmaceutical Ioversol Injection Product Portfolio
- 12.2.5 Zhejiang Starry Pharmaceutical Recent Developments
- 12.3 Hengrui Pharmaceuticals
- 12.3.1 Hengrui Pharmaceuticals Company Information
- 12.3.2 Hengrui Pharmaceuticals Business Overview
- 12.3.3 Hengrui Pharmaceuticals Revenue in Ioversol Injection Business (2021-2026)
- 12.3.4 Hengrui Pharmaceuticals Ioversol Injection Product Portfolio
- 12.3.5 Hengrui Pharmaceuticals Recent Developments
- 12.4 Bayer HealthCare Pharmaceuticals
- 12.4.1 Bayer HealthCare Pharmaceuticals Company Information
- 12.4.2 Bayer HealthCare Pharmaceuticals Business Overview
- 12.4.3 Bayer HealthCare Pharmaceuticals Revenue in Ioversol Injection Business (2021-2026)
- 12.4.4 Bayer HealthCare Pharmaceuticals Ioversol Injection Product Portfolio
- 12.4.5 Bayer HealthCare Pharmaceuticals Recent Developments
- 12.5 Neptunus Bio-pharmaceutical
- 12.5.1 Neptunus Bio-pharmaceutical Company Information
- 12.5.2 Neptunus Bio-pharmaceutical Business Overview
- 12.5.3 Neptunus Bio-pharmaceutical Revenue in Ioversol Injection Business (2021-2026)
- 12.5.4 Neptunus Bio-pharmaceutical Ioversol Injection Product Portfolio
- 12.5.5 Neptunus Bio-pharmaceutical Recent Developments
- 12.6 Liebel-Flarsheim Company LLC
- 12.6.1 Liebel-Flarsheim Company LLC Company Information
- 12.6.2 Liebel-Flarsheim Company LLC Business Overview
- 12.6.3 Liebel-Flarsheim Company LLC Revenue in Ioversol Injection Business (2021-2026)
- 12.6.4 Liebel-Flarsheim Company LLC Ioversol Injection Product Portfolio
- 12.6.5 Liebel-Flarsheim Company LLC Recent Developments
- 12.7 Bracco Imaging S.p.A.
- 12.7.1 Bracco Imaging S.p.A. Company Information
- 12.7.2 Bracco Imaging S.p.A. Business Overview
- 12.7.3 Bracco Imaging S.p.A. Revenue in Ioversol Injection Business (2021-2026)
- 12.7.4 Bracco Imaging S.p.A. Ioversol Injection Product Portfolio
- 12.7.5 Bracco Imaging S.p.A. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst